감염증 진단 시장 : 제품 유형, 샘플 유형, 검사 유형, 병원체 유형, 질환 유형, 최종사용자별 - 세계 예측(2025-2030년)

The Infectious Disease Diagnostic Market was valued at USD 24.07 billion in 2024 and is projected to grow to USD 26.13 billion in 2025, with a CAGR of 8.82%, reaching USD 40.00 billion by 2030.

Unveiling Critical Drivers and Technological Innovations Shaping Modern Infectious Disease Detection

The infectious disease diagnostics arena stands at a pivotal juncture, where technological breakthroughs in instrumentation and software integration converge with rising clinical demands for faster, more precise results. Laboratories and point-of-care settings alike are under increasing pressure to deliver rapid pathogen detection while maintaining rigorous standards of sensitivity and specificity. In this context, stakeholders across the healthcare spectrum-ranging from hospital networks to academic research institutes-must adapt their operational frameworks to harness next-generation tools and workflows.

Against this backdrop, this executive summary synthesizes critical drivers shaping the diagnostics market, highlights regulatory and policy trends influencing global supply chains, and presents actionable frameworks for segmentation, regional analysis, and competitive positioning. By exploring transformative shifts, tariff impacts, and nuanced market segmentation, readers will gain a holistic perspective on how to navigate the complexities of diagnostic innovation, optimize resource allocation, and deliver improved patient outcomes in an increasingly interconnected healthcare ecosystem.

How Automation, Data Analytics, and Decentralized Testing Models Are Revolutionizing Pathogen Detection and Clinical Decision Pathways

The infectious disease diagnostic sector is being reshaped by a convergence of automation, high-throughput capabilities, and data analytics that enable laboratories to process samples at unprecedented scale. Cutting-edge assays compatible with mass spectrometry and next-generation sequencing are complementing immunoassay and PCR technologies, allowing for multiplexed detection of bacterial, viral, fungal, and parasitic pathogens with remarkable turnaround times.

Meanwhile, the integration of cloud-enabled software platforms has streamlined data aggregation from instruments such as immunoassay analyzers and microarrays, supporting real-time surveillance and predictive modeling of outbreak patterns. This shift toward decentralized testing is further bolstered by advanced portable PCR systems and antigen detection kits, extending diagnostic reach beyond centralized labs into point-of-care settings. Consequently, clinical decision-making pathways are evolving to incorporate telehealth consultations informed by rapid test results, signaling a fundamental transformation in how infectious diseases are identified, monitored, and managed on a global scale.

Navigating New Trade Barriers and Strategic Sourcing Adjustments to Sustain Diagnostic Testing Operations Under Evolving Tariff Regimes

Tariff policies implemented throughout 2025 have introduced new cost considerations for imported reagents, instruments, and key components used in infectious disease testing. Many diagnostic laboratories have encountered increased expenses for antigen detection kits and immunoassay analyzers sourced from affected regions, prompting procurement teams to explore alternative domestic suppliers or adjust testing volumes to mitigate budgetary constraints.

In parallel, reagent and kit manufacturers have responded by diversifying regional manufacturing footprints, establishing production lines for ELISA, immunoassay, and PCR kits in tariff-exempt jurisdictions. Software developers for laboratory information management systems have also recalibrated pricing models to accommodate higher import costs for hardware integrations. Collectively, these measures have fostered a more resilient supply chain, though stakeholders must remain vigilant to potential delays and regulatory changes that could further influence global trade dynamics.

Integrating Product, Sample, Testing, Pathogen, Disease, and End-User Perspectives to Illuminate Tailored Diagnostic Pathways

An effective segmentation approach illuminates the nuanced drivers across product categories, revealing distinct adoption patterns in instruments, reagents and kits, and software solutions. Within instruments, immunoassay analyzers maintain strong clinical demand for routine screenings, while mass spectrometers and microarrays cater to specialized research applications. PCR systems continue to expand their footprint in both centralized laboratories and point-of-care settings. Reagents and kits exhibit diverse usage; antigen detection formats excel in rapid testing scenarios, ELISA and immunoassay kits underpin high-throughput workflows, and PCR kits deliver unmatched sensitivity for molecular diagnostics.

Sample type differentiation underscores the importance of specimen matrix compatibility, with blood derivatives such as plasma, serum, and whole blood dominating hospital-based testing and stool and urine assays facilitating gastrointestinal and urinary pathogen detection. Swab collections, spanning nasal, rectal, and throat formats, are pivotal for respiratory screening programs. Diagnostic methodologies fall broadly into laboratory testing and point-of-care modalities, each aligned with specific clinical contexts and throughput requirements. Pathogen focus spans bacterial, fungal, parasitic, and viral targets; within the viral cohort, hepatitis subtypes, HIV, and influenza command critical surveillance priority. Disease classifications span meningitis and pneumonia to vector-borne infections such as dengue and Zika, informing tailored assay development. Finally, end-user environments ranging from academic institutes to diagnostic laboratories and hospitals guide commercialization strategies and service level agreements for comprehensive diagnostic platforms.

Examining Regional Healthcare Infrastructures and Policy Drivers That Shape Diagnostic Innovation and Adoption Patterns Globally

In the Americas region, mature healthcare infrastructures and robust reimbursement frameworks continue to drive adoption of advanced diagnostic platforms. North America's network of reference laboratories and academic research centers spearheads validation of novel assays, while Latin American markets exhibit growing demand for cost-effective rapid tests amid expanding public health initiatives. Economic diversification and government investments in molecular diagnostics have bolstered capacity for large-scale screening programs.

Europe, Middle East, and Africa present a mosaic of requirements, from stringent regulatory compliance in Western Europe to emerging surveillance needs in the Middle East and resource-constrained settings across Africa. Collaborative efforts among public health agencies have accelerated deployment of point-of-care antigen tests and portable PCR systems during outbreak responses, redefining standard practices for decentralized testing.

Asia-Pacific markets showcase dynamic growth fueled by rising awareness of infectious disease preparedness and expanding digital health ecosystems. Government initiatives in countries such as China and India are catalyzing local manufacturing capabilities for reagents and instruments, while Southeast Asian nations integrate multiplexed assays into national screening programs. Across all regions, the convergence of technology, policy, and infrastructure investments is shaping a more agile and responsive diagnostic landscape.

Exploring Strategic Alliances and Platform Integrations Driving Faster Assay Development and Scalable Diagnostic Solutions

Spotlight on Leading Innovators and Strategic Collaborations Elevating Diagnostic Excellence

A cohort of established instrument manufacturers and emerging reagent developers are forging collaborative alliances to accelerate the translation of research-grade assays into clinical practice. Partnerships between microarray providers and software firms have enabled seamless data interpretation pipelines, while joint ventures between kit manufacturers and reference laboratories ensure rigorous performance validation under diverse clinical conditions.

Key diagnostic companies are investing in modular instrument architectures that support rapid assay deployment, leveraging scalable reagent supply chains to meet fluctuating demand during epidemic surges. Software integrators are enhancing interoperability with electronic health record systems to deliver actionable insights directly to clinicians. Collectively, these strategic initiatives underscore a shared commitment to driving continuous innovation, optimizing operational efficiencies, and strengthening the global diagnostics ecosystem through synergistic partnerships.

Building Resilient Manufacturing, Data-Driven Insights, and Collaborative Networks to Accelerate Diagnostic Agility and Market Response

Executives should prioritize the diversification of manufacturing footprints to mitigate supply chain vulnerabilities and reduce exposure to trade policy fluctuations. By adopting flexible production models for key reagents and instruments, organizations can rapidly scale output in response to local outbreak scenarios. Moreover, investing in modular, software-driven platforms will facilitate the seamless integration of new assay chemistries, shortening time to market for emerging pathogen targets.

Leaders must also foster cross-sector collaborations that bridge academic research, clinical laboratories, and public health agencies, creating feedback loops for continuous assay refinement. Embracing data-driven decision-making frameworks-leveraging predictive analytics from real-world testing data-will empower stakeholders to anticipate shifts in pathogen prevalence and deploy targeted diagnostic interventions. Finally, building comprehensive education programs for end-users can drive proficiency in advanced testing methodologies, ensuring optimal utilization of instruments and reagents across diverse care settings.

Detailing Rigorous Data Gathering, Expert Interviews, and Taxonomy Frameworks That Ensure Objective and Actionable Market Analysis

Our analysis synthesizes primary insights from in-depth interviews with senior executives at diagnostic laboratories, kit manufacturers, software developers, and healthcare policymakers. Secondary research leveraged peer-reviewed journals, regulatory filings, and public health agency reports to validate technology adoption trends and regional deployment patterns. Proprietary frameworks were applied to map product and disease classifications, ensuring a consistent taxonomy across instruments, reagents, sample types, and end-user segments.

Quantitative data was cross-referenced with historical trade and policy databases to assess tariff impacts, while real-world usage statistics were examined to refine segmentation insights. Scenario planning exercises facilitated the evaluation of strategic sourcing options and partnership models. All findings were peer reviewed by subject matter experts to ensure accuracy, relevance, and practical applicability for decision-makers seeking strategic guidance in the dynamic infectious disease diagnostics market.

Reinforcing the Role of Adaptive Technologies and Collaborative Strategies in Shaping the Future of Infectious Disease Detection

As the global healthcare ecosystem continues to confront emerging infectious threats, the ability to rapidly detect and characterize pathogens remains the cornerstone of effective response strategies. Technological advancements in assay modalities, combined with robust software integration and decentralized testing capabilities, are redefining diagnostic workflows and enabling proactive patient management.

By embracing diversified manufacturing, leveraging real-world data analytics, and cultivating strategic partnerships, stakeholders can navigate regulatory and trade complexities while delivering high-impact diagnostic solutions. Ultimately, the organizations that align operational agility with a deep understanding of regional and segment-specific dynamics will secure leadership positions and contribute meaningfully to improved global health outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Rising need for rapid diagnostics for early detection of infectious diseases
• 5.2. Adoption of AI-driven predictive analytics optimizing outbreak surveillance and response strategies
• 5.3. Increasing demand for rapid antigen screening in airports and public venues enhancing community safety
• 5.4. Expansion of point-of-care multiplex assays driving decentralized infectious disease testing accessibility
• 5.5. Integration of CRISPR-based diagnostics streamlining rapid pathogen detection workflows
• 5.6. Expansion of telehealth-linked diagnostic platforms accelerating remote infectious disease management
• 5.7. Advancements in next-generation sequencing enabling comprehensive pathogen identification in clinical labs
• 5.8. Shift toward at-home molecular testing kits empowering patient-centric infectious disease monitoring
• 5.9. Genomic tools powering the new era of infection tracking
• 5.10. Implementation of digital biomarkers and wearable sensors to predict infection onset before symptoms

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Infectious Disease Diagnostic Market, by Product

• 8.1. Introduction
• 8.2. Instruments
  • 8.2.1. Immunoassay Analyzers
  • 8.2.2. Mass Spectrometers
  • 8.2.3. Microarrays
  • 8.2.4. PCR Systems
• 8.3. Reagents & Kits
  • 8.3.1. Antigen Detection Kits
  • 8.3.2. ELISA Kits
  • 8.3.3. Immunoassay Kits
  • 8.3.4. PCR Kits
• 8.4. Software

9. Infectious Disease Diagnostic Market, by Sample Type

• 9.1. Introduction
• 9.2. Blood
  • 9.2.1. Plasma
  • 9.2.2. Serum
  • 9.2.3. Whole Blood
• 9.3. Stool
• 9.4. Swab
  • 9.4.1. Nasal
  • 9.4.2. Rectal
  • 9.4.3. Throat
• 9.5. Urine

10. Infectious Disease Diagnostic Market, by Testing Type

• 10.1. Introduction
• 10.2. Laboratory Testing
• 10.3. PoC Testing

11. Infectious Disease Diagnostic Market, by Pathogen Type

• 11.1. Introduction
• 11.2. Bacterial
• 11.3. Fungal
• 11.4. Parasitic
• 11.5. Viral
  • 11.5.1. Hepatitis
  • 11.5.2. HIV
  • 11.5.3. Influenza

12. Infectious Disease Diagnostic Market, by Disease Type

• 12.1. Introduction
• 12.2. Bacterial Infectious Diseases
  • 12.2.1. Meningitis
  • 12.2.2. Pneumonia
  • 12.2.3. Tuberculosis
• 12.3. Fungal Infections
  • 12.3.1. Aspergillosis
  • 12.3.2. Candidiasis
  • 12.3.3. Cryptococcosis
• 12.4. Parasitic Infections
  • 12.4.1. Leishmaniasis
  • 12.4.2. Malaria
  • 12.4.3. Schistosomiasis
• 12.5. Vector-borne Infections
  • 12.5.1. Dengue Fever
  • 12.5.2. Lyme Disease
  • 12.5.3. Zika Virus
• 12.6. Viral Infectious Diseases
  • 12.6.1. Hepatitis (A, B, C)
  • 12.6.3. HIV/AIDS
  • 12.6.4. Influenza

13. Infectious Disease Diagnostic Market, by End-User

• 13.1. Introduction
• 13.2. Academic & Research Institutes
• 13.3. Diagnostic Laboratories
• 13.4. Hospitals & Clinics

14. Americas Infectious Disease Diagnostic Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Infectious Disease Diagnostic Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Infectious Disease Diagnostic Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Bio-Rad Laboratories, Inc.
  • 17.3.2. F. Hoffmann-La Roche Ltd.
  • 17.3.3. Abbott Laboratories
  • 17.3.4. Adaptive Biotechnologies Corporation
  • 17.3.5. Agilent Technologies, Inc.
  • 17.3.6. Becton, Dickinson and Company
  • 17.3.7. Bio-Techne Corporation
  • 17.3.8. bioMerieux SA
  • 17.3.9. Boston Scientific Corporation
  • 17.3.10. Bruker Corporation
  • 17.3.11. Cardinal Health Inc.
  • 17.3.12. Cook Medical Incorporated
  • 17.3.13. Danaher Corporation
  • 17.3.14. GE HealthCare Technologies Inc.
  • 17.3.15. Grifols, S.A.
  • 17.3.16. Hologic Inc.
  • 17.3.17. Illumina, Inc.
  • 17.3.18. Johnson & Johnson Services Inc.
  • 17.3.19. Konica Minolta, Inc.
  • 17.3.20. Koninklijke Philips N.V.
  • 17.3.21. MedMira Inc.
  • 17.3.22. Medtronic PLC
  • 17.3.23. Merck KGaA
  • 17.3.24. Olympus Corporation
  • 17.3.25. Perkin Elmer, Inc.
  • 17.3.26. Pfizer Inc.
  • 17.3.27. Qiagen N.V.
  • 17.3.28. Quest Diagnostics Incorporated
  • 17.3.29. Siemens Healthineers AG
  • 17.3.30. Sysmex Corporation
  • 17.3.31. Thermo Fisher Scientific, Inc.
  • 17.3.32. Trivitron Healthcare

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix